Literature DB >> 30844527

Spheno-Orbital Meningioma: Surgical Outcomes and Management of Recurrence.

Atsufumi Nagahama1, Takeo Goto2, Alhusain Nagm3, Yuta Tanoue2, Yusuke Watanabe2, Hironori Arima2, Kosuke Nakajo2, Hiroki Morisako2, Takehiro Uda2, Tsutomu Ichinose2, Kazuhiro Yamanaka2, Kenji Ohata2.   

Abstract

OBJECTIVE: Spheno-orbital meningioma (SOM) is a rare intracranial tumor that arises at the sphenoid wing, extends into the orbit, and is associated with hyperostosis of the sphenoid bone. These tumors often invade important neurovascular structures around the orbital apex, superior orbital fissure, and cavernous sinus. Aggressive tumor removal could achieve acceptable control; however, residual tumor can regrow. In this article, our surgical management and long-term outcomes are described.
METHODS: Retrospectively, 12 patients with SOM who were treated surgically over a 21-year period were included. The clinical features and long-term tumor control were evaluated.
RESULTS: Participants comprised 12 patients (5 men and 7 women). Mean follow-up was 74.4 months (range, 10-262 months). Ten patients (83%) were identified as World Health Organization grade 1 (WHO-I), and 2 patients (17%) were identified as WHO grade 2 (WHO-II). We encountered 4 recurrences, 2 of which needed additional surgeries. One patient with WHO-I (10%) experienced recurrence 10 years after the initial surgery and required a second surgery. Two patients with WHO-I (20%) showed slight regrowth of residual tumor around the superior orbital fissure; nevertheless, additive therapy was not recommended. Despite radical tumor resection, including eyeball and adjunctive radiotherapy for 1 patient with WHO-II, tumor recurrence in the posterior fossa was documented 19 years after the initial aggressive surgery.
CONCLUSIONS: SOM follows a relatively benign clinical course given the invasive radiologic findings. Abnormal bone resection is paramount to prevent early-stage recurrence. Although intradural residual tumor might regrow, additional surgery could achieve reasonable long-term tumor control with better outcome.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hyperostosis; Intraorbital extension; Recurrence; Spheno-orbital meningioma; Surgical strategy

Mesh:

Year:  2019        PMID: 30844527     DOI: 10.1016/j.wneu.2019.02.123

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Visual outcomes endorse surgery of patients with spheno-orbital meningioma with minimal visual impairment or hyperostosis.

Authors:  Amir H Zamanipoor Najafabadi; Stijn W Genders; Wouter R van Furth
Journal:  Acta Neurochir (Wien)       Date:  2020-09-04       Impact factor: 2.216

2.  Spheno-orbital meningiomas: Is orbit reconstruction mandatory? Long-term outcomes and exophthalmos improvement.

Authors:  Alexandra Gomes Dos Santos; Wellingson Silva Paiva; Leila Maria da Roz; Marcelo Prudente do Espirito Santo; Manoel Jacobsen Teixeira; Eberval G Figueiredo; Vinicius Trindade Gomes da Silva
Journal:  Surg Neurol Int       Date:  2022-07-22

3.  Visualization of Resected Area in Endonasal Endoscopic Approach versus Transcranial Approach for Skull Base Meningiomas by Voxel-Based-Lesion Mapping.

Authors:  Hiroshi Uda; Takehiro Uda; Manabu Kinoshita; Haruhiko Kishima; Yuta Tanoue; Atsufumi Nagahama; Toshiyuki Kawashima; Hiroki Ohata; Kosuke Nakajo; Hiroki Morisako; Takeo Goto
Journal:  Brain Sci       Date:  2022-06-30

4.  Progression-Free Survival, Prognostic Factors, and Surgical Outcome of Spheno-Orbital Meningiomas.

Authors:  Waseem Masalha; Dieter Henrik Heiland; Christine Steiert; Marie T Krüger; Daniel Schnell; Christian Scheiwe; Oliver Schnell; Anca-L Grosu; Jürgen Beck; Jürgen Grauvogel
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

5.  High-grade spheno-orbital meningioma in patients with systemic lupus erythematosus: Two case reports and literature review.

Authors:  Sarah Bin Abdulqader; Nasser Almujaiwel; Wafa Alshakweer; Gmaan Alzhrani
Journal:  Surg Neurol Int       Date:  2020-10-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.